<DOC>
	<DOCNO>NCT01776307</DOCNO>
	<brief_summary>This open label , multi-center , Phase 2 study BBI608 combination cetuximab , panitumumab capecitabine patient advance colorectal cancer .</brief_summary>
	<brief_title>A Study BBI608 Adult Patients With Advanced Colorectal Cancer</brief_title>
	<detailed_description>This open label , multi-center , Phase 2 study BBI608 administer combination either cetuximab , panitumumab , capecitabine . A cycle consist daily continuous oral administration BBI608 four week combination either cetuximab , panitumumab , capecitabine .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Signed write informed consent must obtain document accord International Conference Harmonization ( ICH ) , Good Clinical Practice ( GCP ) , local regulatory requirement , permission use private health information accordance Health Insurance Portability Accountability Act ( HIPPA ) prior studyspecific screening procedure . A histologically cytologically confirm colorectal cancer metastatic , unresectable , recurrent . Patients must receive least 2 regimen contain 5Fluorouracil , oxaliplatin , irinotecan . Patients enrol Cetuximab Panitumumab combination arm must colorectal cancer KRas wildtype . ≥ 18 year age . Measurable disease define Response Evaluation Criteria Solid Tumors ( RECIST 1.1 ) . Karnofsky performance Status ≥ 70 % Male female patient childproducing potential must agree use contraception avoidance pregnancy measure study 30 day last BBI608 dose . Females childbearing potential must negative serum pregnancy test . Aspartate transaminase ( AST ) alanine transaminase ( ALT ) ≤1.5 × upper limit normal ( ULN ) , ≤ 2.5 × ULN metastatic liver disease . Hemoglobin ( Hgb ) ≥ 10 g/dl . Total bilirubin ≤ 1.5 × ULN . Creatinine ≤ 1.5 × ULN creatinine clearance &gt; 60 mL/min/1.73 m^2 patient creatinine level institutional normal . Absolute neutrophil count ≥ 1.5 x 10^9/L . Platelets ≥ 100 x 10^9/L . Life expectancy ≥ 3 month . Anticancer chemotherapy , radiotherapy , immunotherapy , investigational agent within four week first dose exception single dose radiation 8 Gray ( equal 800 RAD ) palliative intent pain control 14 day begin administration BBI608 . Surgery within 4 week prior first dose . Any known symptomatic brain metastasis require steroid . Patients treat brain metastasis must stable 4 week completion treatment , image documentation require . Patients must clinical symptom brain metastasis must either steroids stable dose steroid least 2 week prior protocol enrollment . Patients know leptomeningeal metastasis exclude , even treat . Pregnant breastfeeding Significant gastrointestinal disorder ( ) , opinion Principal Investigator , ( e.g. , Crohn 's disease , ulcerative colitis , extensive gastric small intestine resection ) Unable unwilling swallow BBI608 capsule daily . Uncontrolled intercurrent illness include , limited ongoing active infection , clinically significant nonhealing heal wound , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , significant pulmonary disease ( shortness breath rest mild exertion ) , uncontrolled infection psychiatric illness/social situation would limit compliance study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>BBI608</keyword>
</DOC>